Den tilsvarende procentdel var 62% hos dem, der fik simulerede indsprøjtninger, og 64% hos dem, der fik fotodynamisk behandling med verteporfin.
Between 94 and 96% of the patients receiving Lucentis every month experienced no significant worsening of their vision, compared with 62% of those receiving sham injections and 64% of those treated with verteporfin PDT.